✦ LIBER ✦

5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions: The Milan Experience

✍ Scribed by Alaide Chieffo; Valeria Magni; Azeem Latib; Francesco Maisano; Alfonso Ielasi; Matteo Montorfano; Mauro Carlino; Cosmo Godino; Massimo Ferraro; Giliola Calori; Ottavio Alfieri; Antonio Colombo

Book ID: 108161483
Publisher: American College of Cardiology
Year: 2010
Tongue: English
Weight: 256 KB
Volume: 3
Category: Article
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2010.03.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Meta-analysis of Randomized Controlled T

Meta-analysis of Randomized Controlled Trials on the Treatment of Unprotected Left Main Coronary Artery Disease: One-Year Outcomes with Coronary Artery Bypass Grafting Versus Percutaneous Coronary Artery Intervention with Drug-Eluting Stent

✍ Kan Kajimoto; Katsumi Miyauchi; Taira Yamamoto; Hiroyuki Daida; Atsushi Amano 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

Economic outcomes of percutaneous corona

Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: One-year results from the SYNTAX trial

✍ David J. Cohen; Tara A. Lavelle; Ben Van Hout; Haiyan Li; Yang Lei; Katherine Ro 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 2 views

## Abstract Objectives: To evaluate the cost‐effectiveness of alternative approaches to revascularization for patients with three‐vessel or left main coronary artery disease (CAD). Background: Previous studies have demonstrated that, despite higher initial costs, long‐term costs with bypass surgery

One-Year Follow-Up of Nonrandomized Comp

One-Year Follow-Up of Nonrandomized Comparison between Coronary Artery Bypass Grafting Surgery and Drug-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease in Elderly Patients (Aged ≥75 Years)

✍ RABEH GHENIM; JÉRÔME RONCALLI; AMIR M. TIDJANE; VANINA BONGARD; ABDELKADER ZIANI 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB